Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-4 with Immune Checkpoint Inhibitors in Advanced Solid Tumors
NCT03686202Phase 3Active, not recruiting
- Sponsor
- University Health Network
- Start
- Nov 2018
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MET-4 in solid tumor and melanoma (4 arms), sponsored by University Health Network. Primary endpoints: Cumulative relative abundance of immunotherapy-responsiveness associated species at 12 days, Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains at 12 days and 1 more. Started Nov 2018; status: active, not recruiting.
02
Drugs
MET-4
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT03686202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686202.